Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
Insulin stability during microencapsulation and subsequent release is essential for retaining its biological activity. Therefore we investigated a novel solid/oil/water anhydrous encapsulation method with a combination of stabilizers for maintaining the integrity of insulin during formulation and delivery. Two methods were used for preparation of nanoparticles, namely water/oil/water solvent evaporation and s/o/w anhydrous encapsulation to study the influence of the microencapsulation method on nanoparticle characteristics such as size and morphology, drug content, encapsulation efficiency, and in vitro and in vivo release profile. Poly (lactic-co-glycolic) acid (PLGA) with co-polymer ratio 50:50 was selected to prepare drug-loaded nanoparticles. When nanoparticles were prepared by solvent evaporation higher encapsulation efficiencies could be obtained, e.g. 74 +/- 13 with 5% target loading, whereas with 12% target loading, encapsulation efficiency was 27 +/- 8.6. The s/o/w method has a direct influence on the evaluation parameters where very poor encapsulation efficiencies 11 +/- 6.8 (max) were observed. The presence of stabilizers in the nanoparticles resulted in an increase in particle size but a reduction of encapsulation efficiency. Insulin release rate was comparatively higher for the batches prepared by the w/o/w method containing stabilizers than the s/o/w method. Also the presence of stabilizers resulted in sustained release of insulin resulting in prolonged reduction of blood glucose levels in streptozotocin induced diabetic rats. From the in vitro and in vivo studies, it can be concluded that careful selection of processing conditions and combination of stabilizers also result in beneficial effects without compromising the advantages of these delivery systems.
Kumar
P Satheesh
PS
Department of Pharmacy, Shri G. S. Institute of Technology and Science, Indore (M.P), India. satheeshpharmalo@yahoo.com
Ramakrishna
S
S
Saini
T Ram
TR
Diwan
P V
PV
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D007328:Insulin / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D019344:Lactic Acid / Q000737:chemistry*; D008297:Male; D049329:Nanostructures; D010316:Particle Size; D020442:Poloxamer; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D017693:Sodium Bicarbonate; D012995:Solubility; D014199:Trehalose
D001786:Blood Glucose; D005079:Excipients; D007004:Hypoglycemic Agents; D007328:Insulin; D011108:Polymers; D011994:Recombinant Proteins; D020442:Poloxamer; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017693:Sodium Bicarbonate; D014199:Trehalose